आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - salmeterolum xínafóat - innöndunarduft - 50 míkróg/skammt

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol;   - powder for inhalation - 50 mcg/dose - active: salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol   excipient: lactose monohydrate - serevent is indicated for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in adults and children who are receiving inhaled or oral corticosteroids. serevent should be used only as an adjunct to corticosteroids in the management of asthma. serevent should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

सर्बिया - सर्बियाई - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

evropa lek pharma d.o.o. beograd - Салметерол - suspenzija za inhalaciju pod pritiskom - 25mcg/doza

जर्मनी - जर्मन - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

glaxosmithkline gmbh & co. kg (8041694) - salmeterolxinafoat - einzeldosiertes pulver zur inhalation - salmeterolxinafoat (26167) 0,0725 milligramm

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

ltt pharma limited - salmeterol xinafoate - pressurised inhalation suspension - 25 microgram - selective beta-2-adrenoreceptor agonists - selective beta-2-adrenoreceptor agonists - it is indicated for the regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. serevent is also indicated in the prevention of exercise-induced asthma

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salmeterolum - multidosen-inalatore a polvere - salmeterolum 50 µg per salmeteroli xinafoas, lactosum monohydricum a polvere per dosi. - bronchospasmolytikum - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salmeterolum - dosier aerosol - salmeterolum 25 µg di salmeteroli xinafoas, norfluranum per aerosolum per le dosi. dosi per la nave 120. - bronchospasmolytikum - synthetika

स्पेन - स्पेनी - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

glaxosmithkline s.a. - salmeterol xinafoato - suspensiÓn para inhalaciÓn en envase a presiÓn - 25 microgramos/dosis - salmeterol xinafoato 25 microgramos - salmeterol

स्पेन - स्पेनी - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

glaxosmithkline s.a. - salmeterol xinafoato - polvo para inhalaciÓn - 50 microgramos/dosis - salmeterol xinafoato 50 microgramos - salmeterol

स्विट्ज़रलैंड - फ़्रेंच - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salmeterolum - multidosen-inhalateur À poudre - salmeterolum 50 µg de salmeteroli xinafoas, lactosum monohydricum à la poussière pour la dosi. - bronchospasmolytikum - synthetika